Bevacizumab/Erlotinib CombinedBoost Responses in Renal Cell Ca

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 14 No 8
Volume 14
Issue 8

This supplement to Oncology News International includes more than 15 reportson presentations made at the 41st annual meeting of the American Society of Clinical Oncology.Reviews focus on the use of targeted agents in non–small-cell lung cancer and other solid tumors,evaluating the novel therapies bevacizumab, cetuximab, bortezomib, erlotinib, and gefitinib, aloneand/or in combination with other chemotherapy agents. Continuing medical education credit isavailable by completing a post-test and evaluation online at www.cancernetwork.com/cme.

NASHVILLE, Tennessee-Bevacizumab(Avastin) and erlotinib(Tarceva) in combination therapyhave a high level of activity in metastaticrenal cell carcinoma (RCC),according to findings from a multicenterphase II trial with the two targetedagents. David Spigel, MD, associatedirector of Clinical Research atthe Sarah Cannon Research Institute/Tennessee Oncology in Nashville, presentedupdated study results (abstract4540).The phase II trial included 63 patientswith metastatic clear cell RCCwho received bevacizumab and erlotinibdaily until tumor progression. Ofthe 59 evaluable patients, 22% had anobjective partial response using RECIST(response evaluation criteria insolid tumors) criteria and 3% had acomplete response, for an overall objectiveresponse rate of 25% (Figure1). In addition, 40% of those evaluablehad stable disease and median survivaltime was 23 months.'Spectacular' ResponsesThese responses are "spectacular,"noted Nicholas Vogelzang, MD, directorof the Nevada Cancer Institute,Las Vegas, who discussed several presentationson targeted therapies forRCC. The 23-month median survivaltime was particularly impressive, hesaid.The drugs were well tolerated. Themost common grade 3 toxicities werediarrhea, rash, nausea/vomiting, hypertension,and bleeding. Two patientsdiscontinued treatment because ofgrade 3 skin toxicity, and one discontinuedbecause of grade 4 gastrointestinalbleeding.In RCC, the von Hippel-Lindau tumorsuppressor gene is inactivated,which leads to overexpression of genesthat can promote tumor cell growth,including vascular endothelial growthfactor (VEGF), epidermal growth factor(EGF), and platelet-derived growthfactor (PDGF).Bevacizumab targets VEGF and erlotinibtargets the EGF receptor, whileimatinib (Gleevec), another targeteddrug, is directed at the PDGF receptor.A three-drug combination-imatinib,bevacizumab, and erlotinib-is nowbeing tested in a phase I/II trial led bythe same group at the Sarah CannonResearch Institute (abstract 4542). Sofar, the findings suggest activity for thecombination, though there is no indicationthat it will be superior to thetwo-drug combination. Dr. Vogelzangnoted, in addition, that the toxicityof the three-drug regimen was considerablygreater than that of the twodrugcombination.Trials with other targeted therapiesare also under way in RCC, but thedrugs are at an earlier stage of development.Dr. Vogelzang pointed out thatbevacizumab and erlotinib are bothon the market and "presumably beingused." While research will continue,he said, "certainly, standard therapy isabout to change."

Recent Videos
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Related Content